Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

NeRRe Therapeutics is a clinical-stage company developing the neurokinin(NK)-1 receptor antagonist orvepitant for the treatment of common, chronic, and debilitating conditions caused by neural hypersensitivity associated with Substance P/ NK-1 receptor system dysfunction.Our focus with orvepitant is on the disabling chronic cough associated with the rare and terminal lung disease idiopathic pulmonary fibrosis (IPF) for which t...
NeRRe Therapeutics is a clinical-stage company developing the neurokinin(NK)-1 receptor antagonist orvepitant for the treatment of common, chronic, and debilitating conditions caused by neural hypersensitivity associated with Substance P/ NK-1 receptor system dysfunction.Our focus with orvepitant is on the disabling chronic cough associated with the rare and terminal lung disease idiopathic pulmonary fibrosis (IPF) for which there is no approved treatment.NeRRe will now evaluate orvepitant as a treatment for chronic cough in patients with IPF, a rare, progressive, and fatal form of interstitial lung disease

List your booth number for exhibitions, ask us